Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;16(1):13-21.
doi: 10.14802/jmd.22082. Epub 2022 Dec 20.

Multiple System Atrophy: Advances in Diagnosis and Therapy

Hirohisa Watanabe  1 , Sayuri Shima  1 , Yasuaki Mizutani  1 , Akihiro Ueda  1   2 , Mizuki Ito  1   3
Affiliations

Multiple System Atrophy: Advances in Diagnosis and Therapy

Hirohisa Watanabe et al. J Mov Disord. 2023 Jan.

Abstract

This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Keywords: KeywordsaaDisease-modifying therapy; Multiple system atrophy; Neuroinflammation; Oligodendrocyte; α-synuclein.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no financial conflicts of interest.

Figures

Figure 1.
Figure 1.
Summary of the Movement Disorders Society criteria for the clinical diagnosis of multiple system atrophy. OH, orthostatic hypotension; RBD, REM sleep behavior disorders; VD; voiding difficulties; nOH, neurogenic orthostatic hypotension; AF, autonomic failure; RV, residual volume; MRI, magnetic resonance imaging.
Figure 2.
Figure 2.
Proposed pathogenesis in MSA. Research on the characteristic structure of α-synuclein, neuroinflammation involvement, and the interaction between oligodendroglia and neurons is rapidly advancing progress in MSA. MSA, multiple system atrophy.
Figure 3.
Figure 3.
A novel diagnostic marker in MSA. Diagnostic methods for MSA include the development of techniques to detect MSA-type α-synuclein and neurofilament light chain release with the loss of neurons and oligodendroglia, monitoring of characteristic laryngeal findings, and the development of imaging methods combining advanced statistical methods such as artificial intelligence, machine learning, and deep learning. MSA, multiple system atrophy; CSF, cerebrospinal fluid; PD, Parkinson’s disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–676. - PMC - PubMed
    1. Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, et al. Structures of α-synuclein filaments from multiple system atrophy. Nature. 2020;585:464–469. - PMC - PubMed
    1. Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, et al. α-synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23:21–31. - PMC - PubMed
    1. Williams GP, Marmion DJ, Schonhoff AM, Jurkuvenaite A, Won WJ, Standaert DG, et al. T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease. Acta Neuropathol. 2020;139:855–874. - PMC - PubMed
    1. Jucaite A, Cselényi Z, Kreisl WC, Rabiner EA, Varrone A, Carson RE, et al. Glia imaging differentiates multiple system atrophy from Parkinson’s disease: a positron emission tomography study with [11C]PBR28 and machine learning analysis. Mov Disord. 2022;37:119–129. - PubMed

LinkOut - more resources